Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Autoimmune Disorders

  Free Subscription


03.06.2019

1 Ann Neurol
1 Diabetes
3 J Autoimmun
3 J Clin Endocrinol Metab
1 J Immunol
1 J Neuroimmunol
7 J Neurol
1 Lancet Neurol
8 Mult Scler
1 Nat Rev Neurol
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Neurol

  1. VAN LANGELAAR J, Rijvers L, Janssen M, Wierenga-Wolf AF, et al
    Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis.
    Ann Neurol. 2019 May 28. doi: 10.1002/ana.25508.
    PubMed     Text format     Abstract available


    Diabetes

  2. KAESTNER KH, Powers AC, Naji A, Atkinson MA, et al
    NIH Initiative to Improve Understanding of the Pancreas, Islet, and Autoimmunity in Type 1 Diabetes: The Human Pancreas Analysis Program (HPAP).
    Diabetes. 2019 May 24. pii: db19-0058. doi: 10.2337/db19-0058.
    PubMed     Text format     Abstract available


    J Autoimmun

  3. DE BOYSSON H, Liozon E, Espitia O, Daumas A, et al
    Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis.
    J Autoimmun. 2019 May 23. pii: S0896-8411(19)30106.
    PubMed     Text format     Abstract available

  4. WILLIAMS A, Grantz K, Seeni I, Robledo C, et al
    Obstetric and neonatal complications among women with autoimmune disease.
    J Autoimmun. 2019 May 27. pii: S0896-8411(19)30111.
    PubMed     Text format     Abstract available

  5. GUO C, Fu R, Zhou M, Wang S, et al
    Pathogenesis of lupus nephritis: RIP3 dependent necroptosis and NLRP3 inflammasome activation.
    J Autoimmun. 2019 May 24. pii: S0896-8411(19)30243.
    PubMed     Text format     Abstract available


    J Clin Endocrinol Metab

  6. HJORT R, Lofvenborg JE, Ahlqvist E, Alfredsson L, et al
    Interaction between overweight and genotypes of HLA, TCF7L2, and FTO in relation to the risk of Latent Autoimmune Diabetes in Adults and type 2 diabetes.
    J Clin Endocrinol Metab. 2019 May 24. pii: 5497101. doi: 10.1210/jc.2019-00183.
    PubMed     Text format     Abstract available

  7. FROMMER L, Kahaly GJ
    Autoimmune Polyendocrinopathy.
    J Clin Endocrinol Metab. 2019 Apr 26. pii: 5479350. doi: 10.1210/jc.2019-00602.
    PubMed     Text format     Abstract available

  8. CLOTMAN K, Janssens K, Specenier P, Weets I, et al
    Programmed cell death-1 (PD-1) inhibitor induced type 1 diabetes mellitus: mini-review.
    J Clin Endocrinol Metab. 2018 Jun 27. pii: 5045487. doi: 10.1210/jc.2018-00728.
    PubMed     Text format     Abstract available


    J Immunol

  9. PIANCONE F, Saresella M, Marventano I, La Rosa F, et al
    A Deficit of CEACAM-1-Expressing T Lymphocytes Supports Inflammation in Primary Progressive Multiple Sclerosis.
    J Immunol. 2019 May 29. pii: jimmunol.1801625. doi: 10.4049/jimmunol.1801625.
    PubMed     Text format     Abstract available


    J Neuroimmunol

  10. RASOOLI TEHRANI A, Gholipour S, Sharifi R, Yadegari S, et al
    Plasma levels of CTRP-3, CTRP-9 and apelin in women with multiple sclerosis.
    J Neuroimmunol. 2019;333:576968.
    PubMed     Text format     Abstract available


    J Neurol

  11. LI H, Hu F, Zhang Y, Li K, et al
    Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    J Neurol. 2019 May 25. pii: 10.1007/s00415-019-09395.
    PubMed     Text format     Abstract available

  12. CHALMER TA, Kalincik T, Laursen B, Sorensen PS, et al
    Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
    J Neurol. 2019;266:306-315.
    PubMed     Text format     Abstract available

  13. FISSE AL, Pitarokoili K, Motte J, Gamber D, et al
    Nerve echogenicity and intranerve CSA variability in high-resolution nerve ultrasound (HRUS) in chronic inflammatory demyelinating polyneuropathy (CIDP).
    J Neurol. 2019;266:468-475.
    PubMed     Text format     Abstract available

  14. GAETANI L, Salvadori N, Lisetti V, Eusebi P, et al
    Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.
    J Neurol. 2019 May 25. pii: 10.1007/s00415-019-09398.
    PubMed     Text format     Abstract available

  15. D'AMICO E, Zanghi A, Sciandra M, Borriello G, et al
    Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.
    J Neurol. 2019;266:411-416.
    PubMed     Text format     Abstract available

  16. RAJABALLY YA, Afzal S
    Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2019;266:461-467.
    PubMed     Text format     Abstract available

  17. LAURIDO-SOTO O, Brier MR, Simon LE, McCullough A, et al
    Patient characteristics and outcome associations in AMPA receptor encephalitis.
    J Neurol. 2019;266:450-460.
    PubMed     Text format     Abstract available


    Lancet Neurol

  18. JOKUBAITIS VG, Probstel AK, Arrambide G, Costello F, et al
    Introducing the International Women in Multiple Sclerosis network.
    Lancet Neurol. 2019;18:521.
    PubMed     Text format    


    Mult Scler

  19. MARRIE RA
    Recognizing the diversity gap in multiple sclerosis.
    Mult Scler. 2019 May 28:1352458519850070. doi: 10.1177/1352458519850070.
    PubMed     Text format    

  20. CAPONE F, Collorone S, Cortese R, Di Lazzaro V, et al
    Fatigue in multiple sclerosis: The role of thalamus.
    Mult Scler. 2019 May 29:1352458519851247. doi: 10.1177/1352458519851247.
    PubMed     Text format     Abstract available

  21. MOBERG JY, Laursen B, Thygesen LC, Magyari M, et al
    Reproductive history of the Danish multiple sclerosis population: A register-based study.
    Mult Scler. 2019 May 30:1352458519851245. doi: 10.1177/1352458519851245.
    PubMed     Text format     Abstract available

  22. ARROYO R, Bury DP, Guo JD, Margolin DH, et al
    Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
    Mult Scler. 2019 May 30:1352458519849796. doi: 10.1177/1352458519849796.
    PubMed     Text format     Abstract available

  23. PELLEGRINI F, Copetti M, Bovis F, Cheng D, et al
    A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis.
    Mult Scler. 2019 May 30:1352458519849513. doi: 10.1177/1352458519849513.
    PubMed     Text format     Abstract available

  24. AKGUN K, Ziemssen T
    Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis".
    Mult Scler. 2019 May 30:1352458519854263. doi: 10.1177/1352458519854263.
    PubMed     Text format    

  25. SCARPAZZA C, Signori A, Cosottini M, Sormani MP, et al
    Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate.
    Mult Scler. 2019 May 30:1352458519854162. doi: 10.1177/1352458519854162.
    PubMed     Text format     Abstract available

  26. MCCOMBE PA
    Women who contributed to past research in multiple sclerosis.
    Mult Scler. 2019 May 28:1352458519846101. doi: 10.1177/1352458519846101.
    PubMed     Text format     Abstract available


    Nat Rev Neurol

  27. KELSEY R
    Phase II trial of evobrutinib in multiple sclerosis.
    Nat Rev Neurol. 2019 May 24. pii: 10.1038/s41582-019-0212.
    PubMed     Text format    


    PLoS One

  28. KOSKIMAKI F, Bernard J, Yong J, Arndt N, et al
    Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
    PLoS One. 2018;13:e0209326.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: